Allergy Therapeutics plc (AIM: AGY)

London flag London · Delayed Price · Currency is GBP · Price in GBX
4.900
-0.400 (-7.55%)
Nov 19, 2024, 9:00 AM GMT+1
183.24%
Market Cap 262.70M
Revenue (ttm) 55.20M
Net Income (ttm) -40.22M
Shares Out 4.78B
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,174
Open 5.420
Previous Close 5.300
Day's Range 4.900 - 5.500
52-Week Range 1.650 - 6.300
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Dec 24, 2024

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, an... [Read more]

Sector Healthcare
Founded 2004
Employees 612
Stock Exchange London Stock Exchange AIM
Ticker Symbol AGY
Full Company Profile

Financial Performance

In 2024, Allergy Therapeutics's revenue was 55.20 million, a decrease of -7.36% compared to the previous year's 59.59 million. Losses were -40.22 million, -6.63% less than in 2023.

Financial Statements

News

Global Allergy Therapeutics Market Size To Exceed USD 42.5 Billion By 2033 | CAGR Of 6.29%

The Global Allergy Therapeutics Market Size was Valued at USD 23.1 Billion in 2023 and the Worldwide Allergy Therapeutics Market Size is Expected to Reach USD 42.5 Billion by 2033, according to a rese...

5 months ago - GlobeNewsWire

Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”)

3 years ago - GlobeNewsWire

Allergy Therapeutics reports a 6% annualised growth in revenue in fiscal 2020

Allergy Therapeutics plc (LON: AGY) said on Wednesday that sales growth in the next financial year was likely to remain flat as COVID-19 restrictions continue to make people avoid visits to the clinic...

4 years ago - Invezz